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Abstract
Background: Human primary myeloma (MM) cells do not survive in culture; current in vitro and in vivo systems
for growing these cells are limited to coculture with a specific bone marrow (BM) cell type or growth in an
immunodeficient animal model. The purpose of the study is to establish an interactive healthy donor whole BM
based culture system capable of maintaining prolonged survival of primary MM cells. This normal BM (NBM)
coculture system is different from using autologous BM that is already affected by the disease.
Methods: Whole BM from healthy donors was cultured in medium supplemented with BM serum from MM
patients for 7 days, followed by 7 days of coculture with CD138-selected primary MM cells or MM cell lines. MM
cells in the coculture were quantified using flow cytometry or bioluminescence of luciferase-expressing MM cells.
T-cell cytokine array and proteomics were performed to identify secreted factors.
Results: NBM is composed of adherent and nonadherent compartments containing typical hematopoietic and
mesenchymal cells. MM cells, or a subset of MM cells, from all examined cases survived and grew in this system,
regardless of the MM cells’ molecular risk or subtype, and growth was comparable to coculture with individual
stromal cell types. Adherent and nonadherent compartments supported MM growth, and this support required
patient serum for optimal growth. Increased levels of MM growth factors IL-6 and IL-10 along with MM clinical
markers B2M and LDHA were detected in supernatants from the NBM coculture than from the BM cultured alone.
Levels of extracellular matrix factors (e.g., MMP1, HMCN1, COL3A1, ACAN) and immunomodulatory factors (e.g.,
IFI16, LILRB4, PTPN6, AZGP1) were changed in the coculture system. The NBM system protected MM cells from
dexamethasone but not bortezomib, and effects of lenalidomide varied.
Conclusions: The NBM system demonstrates the ability of primary MM plasma cells to interact with and to survive
in coculture with healthy adult BM. This model is suitable for studying MM-microenvironment interactions,
particularly at the early stage of engagement in new BM niches, and for characterizing MM cell subpopulations
capable of long-term survival through secretion of extracellular matrix and immune-related factors.
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Background
Multiple myeloma (MM) is a genetically heterogeneous
hematological cancer in which malignant plasma cells
proliferate in and destroy the bone marrow (BM). Un-
derstanding the complex interactions between these
MM cells and the cells in their microenvironment is cru-
cial for developing new therapies targeting MM and its
associated bone disease.
Although in vitro and in vivo studies of MM cell lines
are abundant, studies of primary MM cells are limited,
often due to difficulties with maintaining primary MM
outside the functional BM. Survival and growth of pri-
mary human MM cells and cell lines have been demon-
strated in coculture with mesenchymal cells [1–5],
osteoblasts [6], osteoclasts [7], macrophages [8], and
dendritic cells [9]. A 3D autologous BM system, contain-
ing microenvironmental cells already affected by the dis-
ease, has been established to study survival of MM cells
and their precursors in vitro [10]. Growth of human pri-
mary MM plasma cells has also been demonstrated in
animal models, including SCID-hu [11, 12], SCID-rab
[13–15], and scaffold-based [16] models, and growth of
so-called MM stem cells—either clonotypic B lympho-
cytes or phenotypically immature MM cells—has been
demonstrated in nonobese diabetic/severe combined im-
munodeficiency (NOD/SCID) mice [17, 18]. Almost all
in vivo models that use human MM cells have per-
formed studies in immunodeficient mice that fail to ex-
hibit immune cell-driven tumor growth dynamics. In
contrast, certain in vivo murine MM models such as the
5TMM model [19] or transgenic mouse models [20]
have been successfully exploited for studying MM-
immune cell interaction and immunotherapy [21, 22].
To fill the existing need, we developed a novel com-
prehensive in vitro coculture model—the normal bone
marrow (NBM) system—that contains cell types of
healthy donor BM, including immune cells, which are
precultured with serum from MM patients before being
used for coculture with primary MM plasma cells. This
NBM model is different from previous models that co-
culture MM cells with single types of BM cells [7] or
that use autologous BM already affected by the disease
without consideration of the heterogeneous nature of
MM [10]. We demonstrate here that the NBM system
consistently supports long-term survival of primary MM
plasma cells. Our work establishes an in vitro culture
system to mainly maintain primary MM cells and identi-
fies some factors pertinent to MM survival in a whole-
BM microenvironment.
Methods
Primary MM cells and MM cell lines
Primary MM cells were obtained from heparinized BM as-
pirates from patients with active MM during scheduled
clinic visits. Signed Institutional Review Board–ap-
proved informed consent forms are on record. BM
samples were separated by density centrifugation with
Ficoll-Paque (specific gravity, 1.077 g/ml; Amersham
Biosciences, Piscataway, NJ). Plasma cells were isolated
with CD138 immunomagnetic bead selection and auto-
MACs automated separation system (Miltenyi-Biotec,
Auburn, CA). Purity of CD138+ primary samples was
routinely >90 %, as assessed by flow cytometry [7].
For in vitro bioluminescence-based assays of patients’
MM cells, we used patients’ cases in which their MM
cells were capable passaging in SCID-rab mice as de-
scribed [23]. Passaged MM cells were plated in 24-well
plate (100,000 cells/well) and transduced by adding the
lentiviral particles expressing both enhanced green fluor-
escent protein (EGFP) and luciferase to cell suspensions
at MOI (multiplicity of infection) of 2 for 24 h [23],
followed by engraftment of these cells in SCID-rab mice.
Following establishment of high tumor burden as
assessed by periodic measurement of human immuno-
globulins in mice sera and by live-animal imaging [23],
tumor cells were then extracted from the implanted
bone and EGFP/luciferase-expressing MM cells were
sorted by FACS based on EGFP expression. The sorted
MM cells were subsequently engrafted and passaged in
SCID-rab mice. EGFP/luciferase-expressing MM cells
extracted from these mice were used in indicated cocul-
ture experiments.
The stroma-dependent JB MM cell line was estab-
lished at our institute and grown as described [23]. The
stroma-independent cell line OPM2 was obtained from
American Type Culture Collection (ATCC; Manassas,
VA) and ARP1 line was established in our institute.
NBM coculture system
Preparation of the NBM system is illustrated in
Fig. 1a. Freshly obtained (via overnight shipping)
whole BM cells from healthy adult (>40 years old)
donors (n = 20, Allcells, Alameda, CA) were lysed
with RBC lysis buffer (Qiagen Sciences, Germantown,
MD) for 20 min on ice. Cells were centrifuged, and
pellets were washed three times in phosphate-buffered
saline (PBS) and resuspended (2 × 106 cells/ml) in
αMEM medium (Gibco, Grand Island, NY) containing
10 % fetal bovine serum and 10 % serum from MM
patients. Patient serum was used to pre-condition the
NBM culture and emulate a supportive microenviron-
ment before adding MM cells. Typically, serum from
patients with active MM (mostly newly diagnosed cases)
was pooled and aliquots were stored at −80 °C for avail-
ability. BM cells were seeded on a 24-well plate (2 × 106
cells/well in 1 ml) and 96-well white plate (400,000 cells/
well in 200 μl) and were incubated for 7 days at 37 °C;
MM plasma cells then were added to each well (4 BM
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cells: 1 MM cell). In general, each donor’s BM sample was
used for running >15 coculture experiments. MM cells
were quantified with flow cytometry on days 1 and 7 or
with bioluminescence (Veritas microplate luminometer;
Turner Biosystems, Sunnyvale, CA) on days 1 and 5. Test-
ing anti-MM clinical agents in the NBM system was based
on the bioluminescence method using EGFP/luciferase ex-
pressing MM cells.
Fig. 1 Characterization of the NBM coculture system. a A schematic representation of NBM coculture system, showing formation of adherent and
nonadherent BM compartments upon culture with patient serum. In this system, MM cell growth is measured with CD45/CD38 flow cytometry or
direct bioluminescence of luciferase-expressing MM cells from day 1 to 7 of coculture. At these time points, conditioned medium and distinct
cellular compartments including MM cells can be collected or purified for further analysis. b Prior to initiation of coculture, whole BM cells from
healthy donors were cultured for 7 days in medium supplemented with MM patients’ serum; this was followed by 7 days without (top panel,
NBM) or with (bottom panel, NBM +MM) MM cells. The whole BM was subjected to flow cytometry analysis of CD3 T cells, CD19 B cells, CD33
monocytes and CD56 NK cells. Percent values of each type of the cell in the NBM culture are shown. c Phase contrast images from coculture
system (10X magnification): (upper left panel) multinucleated osteoclast-like cell (OC); (lower panel) cells that resemble macrophages (Mφ) and
mesenchymal stem cells (MSC). Giemsa staining of nonadherent cells (upper right panel) from coculture system: typical hematopoietic cells such
as lymphocytes (Lym) and monocytes (MO), and MM plasma cells (MM). d Phase contrast images (20X magnification) of adherent BM cells from
coculture system: immunocytochemical staining of macrophages (Mφ) expressing CD68 (right)
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Flow cytometry
BD FACSVerse (BD Biosciences, San Diego, CA) was
used for flow cytometric analyses. For phenotypic exam-
ination of normal BM culture, nonadherent cells were
collected and remaining adherent cells were incubated
in 0.5 ml StemPro Accutase cell dissociation reagent
(Life Technologies, Grand Island, NY) for 10–20 min at
37 °C. These detached adherent cells were then added to
previously collected nonadherent cells. Cells were washed
with PBS, resuspended in incubation buffer (0.5 % bovine
serum albumin [BSA] in PBS), and stained with multicolor
markers (FITC-anti-CD3, PE-anti-CD33, PE-Cy7-anti-
CD19, APC-anti-CD56; BD Biosciences) for 15 min at
room temperature in the dark. Cells were washed and re-
suspended in 400 μl PBS before analysis.
To identify MM plasma cells in coculture with normal
BM, total cells were collected as described above. Cell
aliquot was stained with 0.02 % crystal violet (LabChem
Inc, Pittsburg, CA) for 10 min and counted on a
hemocytometer. MM cells were delineated from BM cells
with staining for PE-anti-CD38 and FITC-anti-CD45 (BD
Biosciences) as described [7, 24]. Percent plasma cells
based on CD45/CD38 staining, was used to calculate the
absolute number of MM cells from the counted total num-
ber of cells of the corresponding sample.
Cell membrane labeling dye PKH26 (Sigma Aldrich,
St. Louis, MO) was used to show sequential loss of sig-
nal in proliferating MM cells in the NBM coculture
system.
Immunocytochemistry
NBM cells were cultured for 7 days on chamber slides
(Lab-tek, Rochester, NY). Nonadherent cells were washed
away, and adherent cells were fixed with HistoChoice
(AMRESCO, Solon, OH), followed by antigen retrieval
using a water bath at 80 °C for 25 min. After peroxidase
quenching with hydrogen peroxide (3 %) for 5 min, fixed
cells were incubated with mouse anti-human CD68
(Abcam, Cambridge, MA) for 60 min, and the assay was
completed with Dako’s immunoperoxidase kit (Dako
Corp., Carpintera, CA). Cells were lightly counterstained
with hematoxylin. An Olympus BH2 microscope
(Melville, NY) was used to obtain images with a SPOT 2
digital camera (Diagnostic Instruments, Inc., Sterling
Heights, MI). Adobe Photoshop version 10 (Adobe
Systems, San Jose, CA) was used to process the images.
5-bromo-2-deoxyuridine (BrdU) labeling index
APC BrdU Flow Kit (BD Biosciences) was used to com-
pare cell proliferation. At the end of 7 days, cocultured
cells were incubated with 10-μM BrdU for 2 h. MM cells
were separated from the NBM coculture by using
CD138-immunomagnetic beads and then fixed, permea-
balized, treated with DNase (to expose incorporated
BrdU), and stained with fluorochrome-conjugated anti-
BrdU antibody. MM cells separated from coculture but
not exposed to BrdU were used as a control. BrdU label-
ing was measured with flow cytometry.
Osteoclasts and mesenchymal stem cell (MSC) cultures
Cultures of osteoclasts and MSCs were prepared as pre-
viously described [1, 7]. For comparing growth of MM
cells in different coculture systems, indicated luciferase-
expressing MM cells (104 cells/well) were cultured alone
or cocultured for 4 days with NBM cells, osteoclasts or
MSCs in 96-well plates in αMEM medium supple-
mented with 10 % serum pooled from MM patients (10
wells/group/cell line). Growth of MM cells was assessed
with bioluminescence assays, as described above.
NBM coculture system cytokine secretion
Conditioned medium was collected after 7 days of cultur-
ing NBM with MM patients’ serum in the absence (BM
alone) and presence (NBM coculture) of CD138+ MM
cells. Multi-Analyte ELISArray Kit (Qiagen, Valencia, CA)
was used to analyze IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-
13, IL-17A, IFN-γ, TNF-α, G-CSF and TGF-β1 levels in
the culture supernatant. Briefly, supernatant samples
(50 μl) were incubated for 2 h in microplates precoated
with capture antibodies, followed by steps provided in the
manufacturer’s protocol. Plate absorbance was measured
at 450 nm, and background was subtracted with readings
at 570 nm.
Identification of secreted factors in the NBM system by
proteomics
MM cells were cultured alone or with the established
NBM cells (NBM/MM coculture). Separate wells of BM
cells cultured alone (without MM cells) served as a con-
trol. All three groups contained patient serum from the
same source. The experiment was repeated three times
using three different patient MM cells and BM cells
from three healthy donors. In each set of experiments,
after 3 days of coculture, nonadherent cells were col-
lected, washed three times with PBS, and added back to
the original wells containing adherent cells (which were
also washed three times with PBS) in phenol red free
αMEM medium (Gibco) in serum-starved condition.
Similar wash was performed for MM cells cultured alone
or BM cells cultured without MM cells. After 18 h of
culture, the supernatant from each group (MM cells,
BM cells or NBM/MM coculture) was collected and
subjected to proteomic analysis. After concentrating pro-
teins from equal volumes of the supernatant samples
from each group, samples were electorphoresed on a gel,
lanes were cut from the gels, gel pieces were trypsin
digested, and resulting samples were loaded on a mass
spectrometer. The final analysis considered proteins that
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were significantly different (p < 0.05 by t-test) in the
supernatant samples of NBM/MM coculture than in
MM cells or BM cells cultured alone.
Statistical analyses
All values are expressed as mean ± standard error of the
mean, unless indicated otherwise. Student’s t-test or un-
paired t-test were used to analyze the effect of anti-MM
agents in the NBM system.
Results
Characterization of MM cell coculture with BM
established from healthy donor
The NBM coculture system was established for studying
survival and growth of primary MM cells within a
hematopoietic BM and is composed of adherent and
nonadherent healthy adult BM cells and serum pooled
from MM patients (Fig. 1a). Flow cytometry revealed that
the nonadherent cell compartment contained typical
hematopoietic cells, such as CD33high monocytes, CD19+ B
lymphocytes, CD3+ T lymphocytes and CD56+ natural
killer cells (Fig. 1b). The adherent cell compartment mainly
contained cells morphologically resembling macrophages,
as well as few osteoclasts, megakaryocytes and MSCs
(Fig. 1c). Immunohistochemically staining for CD68 con-
firmed abundancy of macrophages in the adherent BM
compartment (Fig. 1d). At this point, after the healthy
donor BM cells had been cultured for 7 days with patient
serum, freshly obtained CD138-selected primary MM cells
[25] were added to the cultures (ratio of 4 BM cells: 1 MM
cell). After 7 days of coculture, survival of MM cells was de-
termined by assessing the proportion of MM plasma cells
to the total number of cells in the culture. MM plasma cells
were identified by low to intermediate expression of CD45
together with high expression of CD38. Lack of expression
of CD19 in MM cells and their position remained similar
after coculture. We examined MM cells from 60 patients; a
significant proportion of MM cells survived in all cases,
regardless of the molecular features of the patient’s MM
cells [25, 26] (Fig. 2a and b), and viability of MM cells
and BM cells during the span of these experiments was
high (>90 %) as assessed by trypan blue exclusion (data
not shown). The NBM cultures were prepared from
more than 20 healthy donors, and MM cells from several
patients were typically cocultured and tested with NBM
cultures from each donor. Using CD138 as another
marker for quantifying MM cells produced results
consistent with those based on CD45/CD38 analysis
(Additional file 1: Figure S1).
Survival and growth of primary MM cells and cell lines
were variable in the NBM system
To assess survival and growth of primary MM cells, we
compared the total number of MM cells on days 1 and 7
(Patients 1–20, Additional file 2: Table S1). Overall, the
numbers of MM cells were significantly different between
day 1 and 7 (p < 0.037). Moreover, in 14 of 20 experi-
ments, the number of MM cells was 59 % (±12 %) higher
on day 7 (p < 0.0005, n = 14) (Fig. 2b), reflecting the het-
erogeneous nature of the disease as seen in patients’ char-
acteristics (Additional file 2: Table S1). MM cell
proliferation on day 7 was evident by BrdU incorporation
in MM cells separated from the coculture system (Fig. 2c)
and by the loss of cell membrane dye PKH26 in cocul-
tured MM cells (Fig. 2d). In the NBM coculture system,
primary MM cells were also capable of prolonged survival
(28 days) through multiple passages in freshly established
NBM cultures (Additional file 3: Figure S2A). These data
validate the NBM system, indicating that primary MM
cells are capable of survival and growth in coculture with
adult human BM containing various types of immune
cells.
Because MM cells are known to closely interact with
cellular elements within the BM microenvironment [7],
use of the NBM system was further analyzed with bio-
luminescent MM cell lines, which is an efficient approach
to examine tumor growth and effects of anti-MM drugs
[2, 27]. Our bioluminescent MM cell lines, constructed
with lentiviral particles containing an EGFP/luciferase
construct, allow tumor cell growth to be monitored with-
out separating the cells. Bioluminescent MM cells that
were used included IL-6-dependent INA6 cell line;
stroma-dependent JB cell line [23]; stroma-independent
OPM2, ARP1 and H929 cell lines; and two patients’ MM
cells that are passaged in SCID-rab mice [23]. INA6, JB,
OPM2, ARP1 and H929 cell lines had higher growth rates
in the NBM coculture system than under their standard
growth conditions (Fig. 2e). Bioluminescence of the pa-
tients’ MM cells was also higher on day 5 than on day 1
(Fig. 2f) indicating MM growth.
To determine whether MM cell growth was affected by
the source of serum (i.e., patients’ versus healthy donors’)
used in the NBM system, serum from healthy donors was
substituted into the model (all other parameters were
unchanged). On day 7, cocultures that used serum from
healthy donors had fewer MM cells than did those that
used serum from MM patients (Additional file 3:
Figure S2B). This indicates that patient serum is an
important component in this coculture model for
maintaining MM cells.
Because the NBM system contains adherent and nonad-
herent BM cells, we investigated whether these compart-
ments support MM growth differently. After 7 days of
NBM culture, we separated nonadherent BM cells from the
adherent BM cells. MM cells expressing luciferase were
cocultured with total NBM cultures or with the separate
adherent and nonadherent portions; MM cell growth
(based on bioluminescence) was compared after 5 days.
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Fig. 2 (See legend on next page.)
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Growth of IL-6-dependent MM line INA6 and stroma-
independent line ARP1 was higher in coculture with non-
adherent than with adherent NBM. In contrast, growth of
the stroma-dependent line JB was higher in coculture with
adherent than with nonadherent NBM (Fig. 3a). One of the
patient’s MM cells were supported mainly by adherent
NBM, but the other patient’s MM cells grew in all NBM
compartments (Fig. 3b). These results suggest that the
NBM system variably supports MM cell survival through
its adherent and nonadherent compartments.
Growth comparison of MM cells in coculture with NBM
cells, osteoclasts and MSCs
In vitro, BM stromal cells such as MSCs and osteoclasts
have been shown to support MM cell survival and
growth [7]. Therefore, we compared growth of MM cells
in coculture with the NBM system with growth in other
routinely used coculture models that contain single type
of BM cells (MSCs or osteoclasts). Luciferase-expressing
INA6 and ARP1 MM cell lines and luciferase-expressing
primary MM cells each were cultured in equal numbers
Fig. 3 Adherent and nonadherent compartments of NBM coculture system support MM growth in a variable manner. Bioluminescence analysis
of (a) luciferase-expressing MM lines (INA6, ARP1, JB) and (b) luciferase-expressing patient MM cells (maintained by passaging through SCID-rab
mice; Pt#15, Pt#21) after 5 days of coculture; analysis of total NBM coculture (Total), adherent compartment only (Adh) or nonadherent compartment
only (Non-Adh)
(See figure on previous page.)
Fig. 2 Patients’ MM cells survive and grow in NBM coculture system, regardless of relevant molecular features. a Four representative patient
samples analyzed by CD45/CD38 flow cytometry to determine percent MM cells in the NBM coculture system on days 1 and 7. b Changes in
number of MM cells after 7 days compared to day 1 of coculture. MM cells from 20 patients characterized according to molecularly defined risk
(low or high) [26] and molecular subtype (MS, CD-1, CD-2, LB, HY, PR, MF) [25]. In 14 of 20 experiments, the number of MM cells was 59 ± 12 %
higher on day 7 than on day 1 (p < 0.0005). p < 0.037 for all 20 samples. c Incorporation of BrdU (detected by flow cytometry) in MM cells separated
from the coculture system after 7 days. Coculture was unexposed (CONT) or exposed to BrdU for 2 h before analysis. d (Left panel) Flow cytometry
analysis of membrane-bound PKH26 dye in CD45/CD38 gated MM cells (Pt#18) in the NBM coculture system on days 1 and 7, showing the loss of
PKH26 signal in the proliferating MM cells. (Right panel) Histogram of PKH26 dye from CD45/CD38 gated MM cells on day 1, 3, 5 and 7 of coculture;
decreasing heights of histogram peaks indicate that most MM cells disappear over time, but a small subpopulation persists and proliferates.
e Bioluminescence analysis of luciferase-expressing stroma-dependent MM cell lines (INA6, JB) cocultured in the NBM system for 1 and 5 days and of
luciferase-expressing standard MM lines (OPM2, ARP1, H929) cocultured in the NBM system (black bars) or cultured in their standard conditions (gray
bars) for 5 days. f Bioluminescence analysis of luciferase-expressing patients’ MM cells on days 1 and 5 in the NBM coculture system
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in the appropriate standard culture conditions and in co-
culture with MSCs, osteoclasts or the NBM system. All
three coculture systems enhanced growth of MM cells
compared to MM cells cultured alone (Fig. 4), and
growth of all three was similarly sustained by coculture
with osteoclasts and the NBM system. Coculture with
MSCs variably supported growth of INA6 cells and pa-
tient MM cells compared to coculture with NBM cells
and osteoclasts (Fig. 4). These results validate the NBM
system as a reliable culture model that supports MM
growth in vitro, similar to coculture models containing
only osteoclasts or MSCs, and it simultaneously provides
a platform for MM cells to interact with immune and
stromal cells in BM.
T cell-related cytokine secretion in the MM-NBM coculture
system
Cytokines play important role in MM cell growth and im-
mune modulation in BM microenvironment, especially
MM cell interaction with T cells [28]. We preformed cyto-
kines array on conditioned media from NBM culture
alone or coculture with patient MM cells after 7 days.
Levels of IL-6 and IL-10 were elevated upon coculture of
MM cells in NBM (Fig. 5a). TGFβ-1 secretion was slightly
decreased upon coculture, while IL-2, IL-4, IL-5, IL-12,
IL-13, IL-17A, IFN-γ, TNF-α and G-CSF were unchanged
(data not shown). These data show sustained secretion of
cytokines, previously reported in MM progression, during
coculture of MM cells in the NBM system.
Proteomics identified secreted factors in the NBM system
We examined proteins secreted by MM cells and BM
microenvironmental cells within the NBM system. In
order to determine the overall effect of MM and BM
cells on each other within the NBM system, we per-
formed protein profiling of the supernatant samples
from the culture of MM cells or BM cells as well as the
coculture of NBM/MM cells, using MM cells from 3 pa-
tients and BM from 3 different healthy donors. Cumula-
tively, 1843 different proteins were detected in at least
one of the three groups. Of the 1843 proteins, 89 pro-
teins were significantly changed in the NBM cocultures
as compared to BM or MM cells cultured alone (Fig. 5b;
Additional file 4: Table S2). These proteins included
clinical MM markers B2M and LDHA, which were more
abundant in the NBM/MM group than in NBM (>2–2.4
fold increase, p < 0.04). Seventy eight of the those 89
proteins were detected at high levels in the NBM cocul-
ture supernatants; these proteins were undetected or de-
tected at low levels in the supernatants from BM or MM
cells cultured alone. Similarly, 11 proteins were un-
detected or identified at low levels in the NBM coculture
supernatants, in comparison to BM or MM cells cul-
tured alone. These proteins differentially secreted in the
NBM coculture system indicate changes in MM cells
and BM microenvironmental cells that are induced by
their effects on each other.
MM cells directly and indirectly impose changes in
the BM milieu that can alter remodeling of the BM
extracellular matrix and regulation of immune compart-
ment [29]. MMP1, important for MM invasion and se-
creted by MM stromal cells, was present at increased
levels in NBM coculture supernatants [30], as were
HMCN1, a mediator of cytokinesis [31], and PLOD3, an
extracellular matrix glycosyl transferase enzyme [32].
However, structural proteins of the extracellular matrix,
such as COL3A1, COL1A1 and ACAN (a proteoglycan),
were detected at lower levels in NBM coculture than in
the BM cells cultured alone. Other factors upregulated
in NBM coculture included proteins associated with al-
teration of antigen-presentation (LILRB4, HLA-B) [33],
regulation of inflammation, and inhibition of T-cell re-
sponse (ITGB2, LRRFIP1, PTPN6) [34–36]. Factors re-
lated to innate immune response (AZGP1, AXL) [37–39]
were present at decreased levels in the NBM coculture su-
pernatants. Increased levels of proteins associated with
exosome miRNA loading (HNRNPA2B1) [40] and ves-
icular constitution (SEC23A, EEA1) [41, 42] indicate
communication between stromal and MM compart-
ments. Proteins important for tumor cell survival
(SND1) [43], proteins known to be expressed by MM
cells (PPA1, CCT3, NME1, SPAG9) [44–47], and a
marker for bone resorption (DPYD) [48] were detected at
higher levels in the NBM coculture supernatants.
Together these findings indicate active communication
among MM cells, immune cells and stromal cells in the
NBM coculture system.
Fig. 4 NBM system supports MM growth as efficiently as coculture
models using MSCs or osteoclasts. Luciferase-expressing MM cell
lines (INA6, ARP1) and patient MM cells (maintained by passaging
through SCID-rab mice; Pt#15) were added to coculture models
(MSCs only, osteoclasts only, NBM system); MM cells cultured alone
(no BM cells) served as a control. Bioluminescence (indicative of MM
cell number) was measured after 5 days; bioluminescence readings
for MM cells on day 0 represent baseline
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Anti-MM efficacy of clinical agents in the NBM system
Because the BM microenvironment confers drug resist-
ance to MM cells [29], we examined the effects of clin-
ical anti-MM agents in the NBM system. We used the
well-characterized OPM2 and ARP1 MM lines, which
are capable of in vitro growth without cellular or cyto-
kine support, as well as patients’ MM cells that have
been maintained by passaging in a SCID-rab mouse; all
types of MM cells used in these experiments express lu-
ciferase. MM cells were cultured alone or cocultured in
the NBM system; cells were treated with dexamethasone
(1–2.5 μM), bortezomib (0.01–5 nM) or lenalidomide
(0.1–5 μM) for 5 days (Fig. 6). In the absence of these
agents, overall growth of OPM2 and ARP1 cells was
profoundly higher in the NBM system than in culture
alone, based on bioluminescence analysis 5 days after
initiation of cultures (see Fig. 2e). All three agents had
variable effects on the growth of MM cells. Dexametha-
sone treatment inhibited growth of OPM2, ARP1 and
the patient’s MM cells cultured alone but not in the
NBM coculture system (Fig. 6a–c). Treatment with bor-
tezomib resulted in growth inhibition of all MM cells in
both culture settings at higher concentration (i.e., 5 nM;
Fig. 6a–c). In the presence of lenalidomide, a lower pro-
portion of OPM2 cells survived in the NBM system than
in culture alone, which is consistent with the agent’s im-
munomodulatory properties (i.e., 1 and 5 μM; Fig. 6a).
In contrast, lenalidomide treatment resulted in stimula-
tion of ARP1 cell growth in the NBM coculture system
and moderately inhibited growth when these cells cul-
tured alone (Fig. 6b). Lenalidomide markedly inhibited
growth of patient’s MM cells in both culture settings, al-
though a higher proportion of residual MM cells were
detected in the NBM coculture system (Fig. 6c). These
data demonstrate that the NBM coculture system effect-
ively supports MM cell survival and growth, but the
anti-MM effects of clinical agents in this system are
highly variable.
Fig. 5 Coculture of MM cells in NBM system induces secretion of factors associated with modification of extracellular matrix and immune
response. a Changes in cytokine (IL-6, IL-10, TGFβ-1) levels in conditioned media from 7-day coculture of three patients’ MM cells with NBM.
Levels are shown as fold-increase of culture system without MM cells (BM). b Proteomics analyses identified factors in NBM/MM coculture supernatant
(increased or decreased levels; p < 0.05; n = 3) compared to supernatant samples of BM cultured without MM cells or MM cells cultured alone. A
thorough list is included in Additional file 4: Table S2
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Discussion
We demonstrated establishment of the novel NBM co-
culture system, where freshly obtained healthy donor
BM cells are cultivated with serum from MM patients,
followed by long-term (7 days) coculture with primary
CD138-selected MM cells or stroma-dependent or -in-
dependent MM cell lines. Regardless of molecular fea-
tures (e.g., risk signature or subset classification) and
presence of allogeneic immune cells (e.g. cytotoxic T
lymphocytes), MM cells from most cases survived and
propagated in this system, and their growth was compar-
able to previously reported coculture systems. Interest-
ingly, few MM cells survived in NBM containing healthy
donor serum, use of patient serum increased MM cell
survival and growth of tumor cells in the NBM coculture
system, which contains typical BM cells mainly of
hematopoietic lineages but also cells of mesenchymal line-
ages. Adherent and nonadherent compartments of the
NBM system variably supported MM growth, and a var-
iety of secreted immunomodulatory cytokines (e.g., IL-10)
and growth factors (e.g., IL-6) were detected in the condi-
tioned medium. This system is clinically relevant because
it allows study of the immediate or initial response of
adult whole BM to the invasion of MM cells and provides
another platform for unraveling the mechanisms by which
MM cells escape immune surveillance.
The NBM system offers advantages for studying clinic-
ally relevant aspects of patient MM cells and their
microenvironment. It is different from an autologous
BM setting that has already been affected by MM and
Fig. 6 The NBM coculture system provides a platform to test MM cell response to clinical agents. Bioluminescence analysis of luciferase-
expressing OPM2 (a), ARP1 (b) and patient MM cells (c; maintained by passaging through SCID-rab mice; Pt#15) cocultured in the NBM system
(black bars) or cultured alone in their standard conditions (gray bars) and exposed to indicated concentrations of dexamethasone, bortezomib
and lenalidomide. Data are represented as percent growth inhibition relative to the respective untreated MM cells (CONT; set to 100 %)
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has varying proportions of non-malignant cells in samples
from different patients [10], and from coculture systems
that are limited to a single type of microenvironmental
cell [1–9]. It is also different from in vivo models for pri-
mary MM that use fetal bone, such as the SCID-hu model
[11, 12], or that lack human hematopoiesis, such as the
calcium phosphate-based scaffold [16]. The findings that
growth of MM cells in the NBM system was comparable
to their growth in coculture with the supportive osteo-
clasts or MSCs further underlines the advantage of this
system for studying MM-microenvironment interactions
due to use of a more comprehensive adult BM content,
particularly immune cells.
The BM microenvironment protects MM cells from
drug-induced cytotoxicity [29]. In this NBM coculture
system, MM cells were protected from dexamethasone,
which is similar to what is observed when MM cells are
cocultured with MSCs or osteoclasts [24]. Bortezomib’s
cytotoxic effects against MM cells were similar whether
cells were cultured alone or cocultured in the NBM sys-
tem. Immunomodulatory agent lenalidomide had con-
trasting effects on MM cell growth in the NBM
coculture system, reflecting its ability to act on MM cells
and immune cells. Lenalidomide had a greater anti-MM
effect against OPM2 cells in the NBM coculture system
than in culture of these cells alone. In contrast, lenalido-
mide stimulated growth of ARP1 cells in the NBM co-
culture system and moderately inhibited growth of these
cells cultured alone, suggesting lenalidomide’s effects on
the BM microenvironment variably impact growth of
MM cells. Indeed, recent study demonstrated the para-
doxical effect of lenalidomide on production of tumor-
promoting cytokines and growth of MM cell lines [49].
Whereas lenalidomide has been shown to be beneficial
for smoldering MM patients who are at risk for develop-
ing active disease and for MM patients with low-risk dis-
ease our findings emphasize the need to address the
utility of IMiDs for MM patients with high-risk disease.
Thus, the NBM coculture system reflects clinical MM
by its ability to support survival of primary MM cells
and variable anti-MM responses to clinical agents, along
with its ability to evaluate simultaneous cytotoxicity on
MM cells and BM cells.
The ability of primary MM cells from certain cases
to cultivate and survive a within nonmyelomatous
hematopoietic environment was previously shown in differ-
ent systems [11–13, 50]. Healthy donor peripheral blood
mononucleated cells preconditioned with IL-2 for 24 h
were able to induce variable immune responses against dif-
ferent MM cell lines in a short bioluminescence-based
assay [27]. We formally described this assay [23] and ex-
panded its use for primary MM cells that are capable of
passaging only in SCID-hu/SCID-rab models. In the syn-
geneic C57BL/KalwRij mouse model, MM cells (5TMM
murine MM cell line or the more aggressive variant 5T33
cell line) are intravenously transplanted into syngeneic,
immunocompetent, C57BL/KalwRij recipient mice and
produce systemic MM [50]. It is likely that certain immune
cells and factors were activated in response to MM in the
5TMM murine model [51] and in the NBM coculture sys-
tem. Thus, the high variability in long-term survival of MM
cells in this allogeneic system (Fig. 2b) could be attributed
to both immune cell response and lack of a sufficiently sup-
portive environment to induce the necessary survival sig-
naling to cells of each case of primary MM. Alternatively, it
is possible that, while a significant proportion of primary
MM cells were initially targeted by immune cells in the
NBM system, a resilient subpopulation of MM cells capable
of survival (due to the presence of patient serum) cultivated
the normal BM microenvironment to allow their propaga-
tion, analogous to dissemination of MM cells in new BM
niches.
Although MM induces phenotypic changes to the cellular
compartments of the BM and modifications to the extracel-
lular matrix and cytokine milieu, there is a lack of in vitro
studies to elucidate these localized molecular changes in
the BM microenvironment. The NBM coculture model
does not use artificial matrix coating (fibronectin, collagen
and matrigel) to study matrix remodeling, but it shows that
such factors can be secreted by the cocultured cells. The
proteomic analysis of NBM supernatant, although descrip-
tive, exposes known and some unknown molecules relevant
to MM pathogenesis. In our system, we observed increased
secretion of collgenase and MMP-1 and decreased secre-
tion of collagens such as COL3A1 and COL1A1 [30]; this
is consistent with conditions important for MM invasion in
the BM niche. Matrix remodeling is further reflected by
changes in high molecular weight extracellular proteins: in-
creased HMCN1 [52] and decreased ACAN [53] in the
NBM coculture conditioned medium. Increased detection
of cell-surface receptor protein ITGB2 suggests dampening
of the TLR-mediated myeloid cell inflammatory response
[34], while increased LRRFIP1 indicates repressed mono-
cyte production of pro-inflammatory cytokine, TNFα [35].
Upregulation of LILRB4, whose ligand is expressed by T
cells, could be implicated in generation of tolerized den-
dritic cells through the action of cytokines IL-10 and
interferon-α [33]. Although TNFRSF17, highly expressed by
MM cells [54], is detected at increased level in NBM cocul-
ture supernatants and is considered a target for therapy in-
volving CAR-expressing T cells. Increased levels of PTPN6
indicate negative regulation of T cell activity [36] in the
NBM system. Downregulation of secreted factors such as
PGLYRP1 [55], a pattern recognition protein, and AZGP1,
which plays a role in MHC antigen processing [37], in the
NBM coculture suggest a diminished innate immune re-
sponse against invasive MM cells. While AXL is shown to
inhibit TLR-mediated immune activity, it is also a soluble
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receptor for GAS6 [38], a survival factor expressed by MM
cells [39]. We did not detect AXL in NBM coculture or
MM cell monoculture, but it was abundant in BM cell
monoculture, suggesting that the GAS-6/AXL axis may not
promote proliferation of MM cells in an allogeneic BM set-
ting. Communication between MM cells and mesenchymal
cells was indicated by increased levels of HnRNPA2B1, a
miR-15a loading protein found in exosomes derived from
patient BM stroma [40, 56, 57]. Vesicular markers, such as
EEA1 [42] and SEC23A [41], were upregulated in NBM co-
cultures, suggesting secretory activity in the BM stromal
compartment. Some proteins detected in NBM cocultures
may be associated with changes in surviving MM cells
themselves (i.e., PPA1, CCT3, NME1, SPAG9); com-
pared to normal plasma cells, we detected high gene
expression of these factors in CD138-sorted cells from
MM patients’ BM (data not shown) [44–47]. We also
detected metabolism-related proteins (WARS, BLVRA)
not previously reported to be secreted but upregulated in
MM cells sensitive to anti-MM agents suggesting their
role in MM survival in BM microenvironment [58, 59].
Altogether, we detected proteins related to immune
deactivation, extracellular matrix modification and
MM survival in the liquid milieu of the NBM cocul-
ture system, possibly providing clues about MM sur-
vival in an allogeneic BM microenvironment. Whether
some of these abnormal changes persist at other clin-
ical stages such as post-treatment and remission, and
contribute to disease progression is a matter of con-
tinual study.
Conclusions
We established the reproducible NBM coculture system
in which healthy adult BM interacts with and supports
growth and survival of primary CD138-selected MM
cells. MM cells or subset of MM cells from most cases
were capable of escaping immune surveillance and
propagate in this system. Adherent and nonadherent
compartments contributed to these effects, and patient
serum was a necessary component. The NBM coculture
system may be a useful model for studying immunologic
and microenvironment aspects of newly colonized bone
marrow and for testing clinically relevant anti-MM
agents in vitro using patients’ MM cells.
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